• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances
Kardiol Pol. 2022;80(12):1200-1210. doi: 10.33963/KP.a2022.0283.ABSTRACTAtherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease (CAD), cerebrovascular disease, and peripheral arterial disease (PAD) is associated with significant morbidity, mortality, and healthcare costs. Antiplatelet therapy has long been the mainstay of antithrombotic therapy for the prevention of first-ever and recurrent ASCVD events. More recently, however, randomized trials have demonstrated the benefits and cost-effectiveness of a dual pathway inhibition (DPI) strategy in acute and chronic ASCVD. When used in combinatio...
Source: Polish Heart Journal - January 5, 2023 Category: Cardiology Authors: Stephanie Carlin Tim Ac de Vries Andrzej Budaj John Eikelboom Source Type: research